CureVac NV
NASDAQ:CVAC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
CureVac NV
Common Stock
CureVac NV
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
CureVac NV
NASDAQ:CVAC
|
Common Stock
€26.9m
|
CAGR 3-Years
6%
|
CAGR 5-Years
107%
|
CAGR 10-Years
N/A
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Common Stock
€259m
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Common Stock
€1.3m
|
CAGR 3-Years
19%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Common Stock
€39.6m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
2%
|
|
|
Heidelberg Pharma AG
XETRA:HPHA
|
Common Stock
€46.8m
|
CAGR 3-Years
0%
|
CAGR 5-Years
9%
|
CAGR 10-Years
N/A
|
|
|
Formycon AG
XETRA:FYB
|
Common Stock
€17.7m
|
CAGR 3-Years
17%
|
CAGR 5-Years
12%
|
CAGR 10-Years
7%
|
|
CureVac NV
Glance View
CureVac BV is a clinical-stage biopharmaceutical company, which engages in developing transformative medicines based on messenger ribonucleic acid (mRNA). The company is headquartered in Tuebingen, Baden-Wuerttemberg and currently employs 500 full-time employees. The company went IPO on 2020-08-14. The firm is engaged in the therapeutic development of messenger Ribonucleic Acid (mRNA) and RNA-based vaccines. CureVac AG focuses on developing vaccines for infectious diseases and drugs to treat cancer and rare diseases. The firm's pipeline focuses on three areas: cancer immunotherapy, prophylactic vaccines, and protein-based therapies.
See Also
What is CureVac NV's Common Stock?
Common Stock
26.9m
EUR
Based on the financial report for Dec 31, 2024, CureVac NV's Common Stock amounts to 26.9m EUR.
What is CureVac NV's Common Stock growth rate?
Common Stock CAGR 5Y
107%
Over the last year, the Common Stock growth was 0%. The average annual Common Stock growth rates for CureVac NV have been 6% over the past three years , 107% over the past five years .
